Literature DB >> 12694322

Dialysis modalities and dyslipidemia.

Per-Ola Attman1, Ola Samuelsson, Ann-Cathrine Johansson, James B Moberly, Petar Alaupovic.   

Abstract

Progressive renal failure is accompanied by dyslipidemia, which is reflected in an abnormal apolipoprotein profile. It is characterized by increased concentrations of intact and partially metabolized triglyceride-rich apoB-containing lipoproteins. They occur preferentially in very-low density lipoprotein (VLDL) and low-density lipoprotein (LDL) as a result of impaired metabolism and clearance. Hemodialysis can moderately attenuate the renal dyslipidemia. In contrast, peritoneal dialysis is associated with further aggravation, including an increase of cholesterol-rich apoB-containing lipoproteins.

Entities:  

Mesh:

Year:  2003        PMID: 12694322     DOI: 10.1046/j.1523-1755.63.s84.3.x

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  10 in total

Review 1.  Dyslipidemia in patients with chronic and end-stage kidney disease.

Authors:  Jad Omran; Ashraf Al-Dadah; Kevin C Dellsperger
Journal:  Cardiorenal Med       Date:  2013-07-13       Impact factor: 2.041

Review 2.  Statins in the management of dyslipidemia associated with chronic kidney disease.

Authors:  Murray Epstein; Nosratola D Vaziri
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

3.  Longitudinal Trend in Lipid Profile of Incident Peritoneal Dialysis Patients is Not Influenced by the Use of Biocompatible Solutions.

Authors:  Yeoungjee Cho; Janine Büchel; Sonja Steppan; Jutta Passlick-Deetjen; Carmel M Hawley; Goce Dimeski; Margaret Clarke; David W Johnson
Journal:  Perit Dial Int       Date:  2015-10-01       Impact factor: 1.756

Review 4.  ESRD-induced dyslipidemia-Should management of lipid disorders differ in dialysis patients?

Authors:  Hamid Moradi; Elani Streja; Nosratola D Vaziri
Journal:  Semin Dial       Date:  2018-04-29       Impact factor: 3.455

Review 5.  Managing dyslipidemia in chronic kidney disease.

Authors:  Daniel E Weiner; Mark J Sarnak
Journal:  J Gen Intern Med       Date:  2004-10       Impact factor: 5.128

Review 6.  Causes of dysregulation of lipid metabolism in chronic renal failure.

Authors:  Nosratola D Vaziri
Journal:  Semin Dial       Date:  2009 Nov-Dec       Impact factor: 3.455

7.  Dysregulation of hepatic fatty acid metabolism in chronic kidney disease.

Authors:  Kyubok Jin; Keith Norris; Nosratola D Vaziri
Journal:  Nephrol Dial Transplant       Date:  2012-10-08       Impact factor: 5.992

Review 8.  HDL abnormalities in nephrotic syndrome and chronic kidney disease.

Authors:  Nosratola D Vaziri
Journal:  Nat Rev Nephrol       Date:  2015-11-16       Impact factor: 28.314

9.  Dyslipidemia associated with chronic kidney disease.

Authors:  Vasilis Tsimihodimos; Zoi Mitrogianni; Moses Elisaf
Journal:  Open Cardiovasc Med J       Date:  2011-02-24

Review 10.  Cholesterol Disturbances and the Role of Proper Nutrition in CKD Patients.

Authors:  Anna Gluba-Brzozka; Beata Franczyk; Jacek Rysz
Journal:  Nutrients       Date:  2019-11-18       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.